Nicotinamide phosphoribosyl-transferases (NAMPT) are enzymes that play a role in targeting cancer metabolism, while beta lactamases are involved in bacterial resistance to beta-lactam antibiotics. Many protein inhibitors exhibit such property which is often correlated with their cellular potency. In order to understand such a phenomenon, the present article conducts an analysis of the dynamic behavior of complexes formed by the inhibitors, that is indolizine derivatives, with the studied enzymes. Both docking and molecular dynamics led to identification of their interactions and showed the mechanism of inhibition of the two studied enzymes. The differences in the behavior of ligand at the active sites of beta lactamases and nicotinamide phosphoribosyl-transferases are indicated by structural and enthalpy values.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487893 | PMC |
http://dx.doi.org/10.1007/s00894-017-3363-3 | DOI Listing |
Mar Drugs
January 2025
Nebraska Center for Virology, School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.
Filoviruses, mainly consisting of the two genera of and , are enveloped negative-strand RNA viruses that can infect humans to cause severe hemorrhagic fevers and outbreaks with high mortality rates. However, we still do not have effective medicines for treating these diseases. To search for effective drugs, we have identified three marine indole alkaloids that exhibit potent activities against filovirus infection.
View Article and Find Full Text PDFMar Drugs
December 2024
School of Pharmaceutical Sciences, GBRCE for Functional Molecular Engineering, Sun Yat-sen University, Guangzhou 510006, China.
One new gliotoxin derivative fumianthrogliotoxin (), one new indoquizoline alkaloid 3-(methyl propionate) indoquizoline (), and three novel indole alkaloids, anthroxyindole (), (±)-asperfumiindole A (), and (±)-asperfumiindole B (), together with 16 known compounds (-), were isolated from the culture of deep-sea derived fungus AF1. Their chemical structures and absolute configurations were determined through the analysis of NMR data in combination with electronic circular dichroism (ECD) calculations and other spectroscopic analyses. Compounds - and - were evaluated for anti-pulmonary fibrosis activity.
View Article and Find Full Text PDFBMC Cancer
January 2025
PET/CT center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, Henan, 450008, China.
Objective: To investigate the predictive value of machine learning-based PET/CT radiomics and clinical risk factors in predicting interim efficacy in patients with follicular lymphoma (FL).
Methods: This study retrospectively analyzed data from 97 patients with FL diagnosed via histopathological examination between July 2012 and November 2023. Lesion segmentation was performed using LIFEx software, and radiomics features were extracted through the uAI Research Portal (uRP) platform, including first-order features, shape features, and texture features.
PLoS One
January 2025
Department of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.
Mushrooms are considered one of the safe and effective medications because they have great economic importance due to countless biological properties. Cordyceps militaris contains bioactive compounds with antioxidant, antimicrobial and anti-cancerous properties. This study was projected to analyze the potentials of biometabolites and to extract antimicrobial peptides and protein from the C.
View Article and Find Full Text PDFBMJ Open
January 2025
Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China
Objective: To evaluate the cost-effectiveness of polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) in CD20-positive patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in China.
Design: A Markov model was constructed to analyse the cost-effectiveness of two strategies in CD20-positive patients with previously untreated DLBCL over a lifetime horizon: (1) pola-R-CHP and (2) rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). The clinical outcomes were obtained from the POLARIX(NCT03274492), SCHOLAR-1, ZUMA-7(NCT03391466) and TRANSFORM(NCT03575351) trials.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!